行情

MGTA

MGTA

MAGENTA THERAPEUTICS, INC.
NASDAQ

实时行情|Nasdaq Last Sale

11.14
-0.16
-1.42%
盘后: 11.14 0 0.00% 16:00 09/18 EDT
开盘
11.35
昨收
11.30
最高
11.59
最低
10.89
成交量
3.61万
成交额
--
52周最高
21.00
52周最低
5.31
市值
3.83亿
市盈率(TTM)
-5.8264
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MGTA 新闻

  • 美联储宣布降息25个基点 特朗普:降得不够多 "失败"!
  • 央视.59分钟前
  • 鲍威尔:美联储或将不得不恢复资产负债表增长
  • 新浪美股.1小时前
  • 尾盘:美股跌幅收窄 道指下跌约100点
  • 新浪美股.1小时前
  • 花旗:美元上涨是因美联储"温和暗示"宽松或已结束
  • 新浪财经.1小时前

更多

所属板块

生物技术和医学研究
-0.89%
制药与医学研究
-0.16%

热门股票

名称
价格
涨跌幅

MGTA 简况

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.
展开

Webull提供Magenta Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。